PCV001 is a precision cancer vaccine designed to prevent the relapse or spread of colorectal cancer. The vaccine is currently undergoing GMP manufacturing and is nearing the start of Phase I clinical studies.
This novel cancer vaccine leverages cutting-edge research to target cancer cells by introducing antigens associated with specific tumour types. These antigens stimulate the immune system, particularly CD8 and CD4 T-cells, to detect and attack cancerous cells. By boosting the body’s immune response, PCV001 aims to reduce the risk of recurrence and enhance the effectiveness of first-line treatments like chemotherapy and radiotherapy.
The upcoming Phase I clinical trial will evaluate the vaccine’s safety, dosage, and efficacy in colorectal cancer patients, laying the groundwork for future studies and broader clinical application.